All News

The Power of a Name

A new study suggests that the name of a biosimilar product could influence pharmacist confidence levels when dispensing a biosimilar in place of a reference biologic.

And as with what seems like every area of healthcare, changes and challenges to the vital supply chain have been coming and will continue to come for the foreseeable future.

Many pharmacists support FDA’s recent warning letters to drug stores, smoke shops, and other retailers over selling e-cigarettes, hookah tobacco, and cigars to minors.

Impossible Task

Managing the costs of specialty pharmaceuticals is a perpetual task for specialty pharmacists.

Somewhere in the United States, there may be a retail or specialty pharmacy that is not part of a group purchasing organization (GPO). If there is such a pharmacy, it is very hard to find.

Caught in the Middle

The furor over EpiPen pricing is simply the best publicized of many similar price hikes that have left patients unable to pay.

While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.

Battling DIR Fees

The profitability of both chain and independent pharmacies is being affected by direct and indirect remuneration fees that insurers are retroactively charging pharmacies after filling Medicare Part D prescriptions.

In patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events

New Mexico's state motto is “The Land of Enchantment,” but it might also be dubbed the The Land of Opportunity. Pharmacists here are increasingly breaking barriers to deliver frontline, provider care services in an environment that fosters innovations for the profession, students, and patients.